GlobeNewsWire
15 Dec 2025, 21:01 UTC · 46w ago
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
Impact · against what's priced in
Monte Rosa Therapeutics is set to release updated interim Phase 1/2 data for MRT-2359 in prostate cancer. As a lead candidate in a high-need oncology area, the actual data outcome will be the primary driver of valuation, though the announcement of the presentation itself serves as a short-term volatility catalyst.
Scored by the NIS engine · methodology.
